Injectable Drug Compatibility News
2027 Y-Site Compatibility Wall Charts Available
Since first introduced in the year 2000 King Guide y-site compatibility wall charts have been a proven, useful reference to have visible in the hospital and pharmacy for situations where a quick 'yes' or 'no' answer is needed. With 122 IV drugs and 4 infusion fluids the wall charts provide a comprehensive view of compatibility for Critical Care Admixtures and Chemotherapy Admixtures on a laminated 27" x 27" wall chart. The information on the charts is updated each year with data from the complete King® Guide to Parenteral Admixtures® database of over 600 fully referenced, peer-reviewed injectable drug compatibility and...
Study Sparks Discussion on Data Accuracy and Clinical Decision Support
IV Compatibility Study Sparks Discussion on Data Accuracy and Clinical Decision Support A recently published study in the European Journal of Clinical Pharmacology has highlighted the potential of electronic tools to support the detection of intravenous (IV) drug incompatibilities in clinical practice. A subsequent correspondence from the editor of King Guide has raised important questions regarding the accuracy of some of the data used in the study, prompting a broader discussion about validation, reference standards, and the role of clinical decision-support systems in medication safety. [link.springer.com], [e-Harvis a...ature Link] Original Study Evaluates e-Harvis Compared to Established References In June 2026,...
Fall 2026 IV Drug Updates
Included in this update is a new monograph for NARSOPLIMAB-wuug. In addition, we included new stability information for the monographs for CLONAZEPAM and ISATUXIMAB. Compatibility information was added to these monographs: AMOXICILLIN SODIUM, AMPHOTERICIN B LIPOSOME, CALCIUM CHLORIDE, CYCLIZINE LACTATE, DOBUTAMINE HYDROCHLORIDE, FUROSEMIDE, HEPARIN SODIUM, HYDROMORPHONE HYDROCHLORIDE, INTRALIPID, ISOSORBIDE DINITRATE, KETAMINE HYDROCHLORIDE, LINEZOLID, MAGNESIUM SULFATE, METOCLOPRAMIDE HYDROCHLORIDE, MICAFUNGIN SODIUM, NOREPINEPHRINE BITARTRATE, POTASSIUM PHOSPHATE, TEICOPLANIN, TRANEXAMIC ACID, VANCOMYCIN HYDROCHLORIDE, and AMOXICILLIN/CLAVULANATE with 20 other drugs.
Summer 2026 - Injectable Drug Updates
We included new stability information to the monographs for: CEFTOBIPROLE MEDOCARIL SODIUM, CEFTAZIDIME, CEFTAZIDIME AND AVIBACTAM SODIUM, ERTAPENEM, MEROPENEM, NALBUPHINE HYDROCHLORIDE, and ORPHENADRINE CITRATE. Compatibility information was added to the monographs for ACYCLOVIR SODIUM, AMIKACIN SULFATE, AMOXICILLIN SODIUM, AMPHOTERICIN B, CEFOTAXIME SODIUM, CEFTRIAXONE SODIUM, CLONAZEPAM, DIAZEPAM, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, FUROSEMIDE, KETAMINE HYDROCHLORIDE, KETOPROFEN, KETOROLAC, METHADONE HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE, MORPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, PANTOPRAZOLE SODIUM, SODIUM BICARBONATE, TRAMADOL HYDROCHLORIDE, and VANCOMYCIN HYDROCHLORIDE.
Spring 2026 - Injectable Drugs Update
In this update, we added a new monograph for TREOSULFAN. We included new stability information to the monograph for EPINEPHRINE HYDROCHLORIDE. Compatibility information was added for AMOXICILLIN/CLAVULANATE mixed with 49 different drugs; and a boxed warning was added to the monograph for TRANEXAMIC ACID.